Envestnet Asset Management Inc. Increases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Envestnet Asset Management Inc. boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 1.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,438 shares of the medical research company’s stock after buying an additional 2,148 shares during the period. Envestnet Asset Management Inc. owned approximately 0.15% of Natera worth $20,298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Principal Securities Inc. acquired a new position in shares of Natera during the fourth quarter valued at about $32,000. GAMMA Investing LLC boosted its stake in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new stake in Natera during the 1st quarter worth approximately $36,000. Tobam purchased a new stake in Natera during the 2nd quarter worth approximately $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in Natera during the 1st quarter valued at approximately $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. BTIG Research lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group lowered their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and set a $150.00 price target on shares of Natera in a research note on Friday, September 13th. TD Cowen raised their price objective on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.07.

Insider Buying and Selling

In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now directly owns 206,400 shares of the company’s stock, valued at $21,211,728. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the transaction, the insider now owns 206,400 shares in the company, valued at approximately $21,211,728. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total value of $185,946.90. Following the completion of the sale, the chief financial officer now owns 71,955 shares in the company, valued at $7,170,315.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,921 shares of company stock valued at $10,551,281. 7.60% of the stock is owned by corporate insiders.

Natera Price Performance

NASDAQ:NTRA opened at $127.78 on Monday. The company has a 50 day moving average price of $114.45 and a 200-day moving average price of $105.54. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01. The firm has a market cap of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the previous year, the business earned ($0.97) EPS. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. Equities research analysts forecast that Natera, Inc. will post -1.96 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.